Aiwu (Ruth) He, PhD, MedStar Georgetown University Hospital, is joined by Mark Yarchoan, MD, Johns Hopkins Medicine; James Harding, MD, Memorial Sloan Kettering Cancer Center; and Namrata Vijayvergia, MD, Fox Chase Cancer Center, for a roundtable discussion on the current and future treatment considerations for advanced HCC.

The panel explores how treatment goals in advanced HCC have evolved, particularly in light of unpredictable long-term responders to immunotherapy. They discuss the balance between extending survival and preserving quality of life, noting the individual nature of care. The